http://biomedreports.com () —
The CEO of Millennium Biotechnologies Group Inc. (OTCBB: MBTG), a product development company for the Clinical Nutrition and Sports Supplement Markets, says his company is at the beginning of their commercialization era and he expects some significant success, "certainly within the next quarter or two."
Mark C. Mirken, President and Chief Operating Officer of Millennium Biotechnologies, Inc., told BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, that his company "is now in discusions with two of the largest bottling companies in the world."
According to the exclusive report, as a competitive response to Pepsi's purchase of Muscle Milk for $600 million, one of those major bottling companies is rumored to be close to investing in MBTG in order to help market its Surgex sports drink line as a competitor (to Muscle Milk).
"Our sports product, Surgex, is an independently, medically validated product with a banned substance control group of athletes that is manufactured by us," explains Mirken. "It is used in the NBA and the NFL and its success comes from the work that went into developing it with strength and conditioning coaches and that product is about to have a significant commercial debut which we will announce in the very near future -- predicated on a relationship that we will create with one of the largest powdered drink manufacturers in the world in maximum human performance; which are their customers and which will take us into over 3000 GNC (General Nutrition Centers, Inc.) stores within the next 30 to 60 days. That product will not only launch as a powder, but it will evolve into a functional beverage, ready to drink within 2 to 3 months."
The complete article, which explains several other pending catalysts for the company is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/34151-millennium-iot echnologies-groups-ceo-says-major-developments-are-underway.html (http://biomedreports.com/articles/most-popular/34151-millennium bio technologies-groups-ceo-says-major-developments-are-underway.html)
Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com (http://BioMedReports.com)